Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ingenious Targeting Laboratories has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. Anne Marie Sabrina Wehbe is the busiest examiner, currently managing 1 pending office action. The company's current prosecution is highly focused. With 1 distinct examiner and 1 distinct art unit, the Biotechnology & Pharmaceuticals filings are concentrated under a single review.
Wehbe is the only examiner with a pending action for this entity. Practitioners can concentrate on the 1 pending office action. Because there is only 1 distinct art unit, the prosecution process is straightforward. The strategy for the portfolio depends on the specific feedback from Anne Marie Sabrina Wehbe. This centralized environment ensures that prosecution efforts are not diluted across multiple examiners, allowing for a direct and efficient response to the single pending office action within the Biotechnology & Pharmaceuticals technology area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEHBE, ANNE MARIE SABRINA | 1 | 57.3% | +43.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18233507 | Genetically modified non-human having humanized gamma and delta TCR variable genes | WEHBE, ANNE MARIE SABRINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18233507 | Genetically modified non-human having humanized gamma and delta TCR variable genes | WEHBE, ANNE MARIE SABRINA | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18233507 | Genetically modified non-human having humanized gamma and delta TCR variable genes | WEHBE, ANNE MARIE SABRINA | 1634 | §103§112 | Non-Final OA | — | Pending | Aug 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIngenious Targeting Laboratories has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Anne Marie Sabrina Wehbe has the most, with 1 of Ingenious Targeting Laboratories's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
